Form 4: Natera President Sells Shares Under 10b5-1 Plan

Natera, Inc. President of Clinical Diagnostics, Solomon Moshkevich, has sold a total of 3,000 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., executed a series of stock sales on April 1, 2026.
• These transactions involved the sale of 1,048 shares at a weighted average price of $201.3206, 1,000 shares at $202.3638, and 952 shares at $203.3106.
• The total number of shares sold amounts to 3,000.
• These sales were conducted under a Rule 10b5-1 trading plan established on November 26, 2024, which is designed to comply with affirmative defense conditions for insider trading.
• Following these transactions, Moshkevich beneficially owns 147,882 shares of Natera's common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the sales were conducted under a pre-established Rule 10b5-1 plan, indicating a planned divestment rather than a reaction to negative company news.

Negatives

• Insider selling, even if conducted under a pre-arranged plan, can sometimes be perceived negatively by the market.

Risks

• The sales were executed under a Rule 10b5-1 plan, which is a standard mechanism for insiders to sell shares without violating insider trading rules, but the existence of such a plan does not eliminate market perception risks associated with insider selling.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider selling under Rule 10b5-1 plans is a common practice for executives to diversify their holdings or meet financial obligations. While these plans are designed to avoid insider trading concerns, significant sales by key executives can sometimes lead to investor scrutiny, depending on the volume and prevailing market conditions.

Stakeholder Impact

• Shareholders may observe the sale of shares by a key executive, which could influence short-term trading sentiment, although the Rule 10b5-1 plan mitigates concerns about insider trading.

Next Steps

• Continued monitoring of insider trading activity for Natera, Inc.

Key Dates

Keywords

Natera Inc, NTRA, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Beneficial Ownership, Solomon Moshkevich, Clinical Diagnostics